title: [The influence of activation of the ATP-sensitive potassium channels by flocalin on the function of the cardiovascular system].
abstract: In experiments on the anaesthetized dogs the influence of a new fluorine-containing opener of ATP-sensitive potassium (K(ATP)) channels flocalin on the cardiohemodynamic of great animals in vivo was studied. Flocalin introduced intravenously in doses 0.01 - 1.5 mgs/kg. It is shown that it reduces in dose-dependent manner a system arterial pressure, perfusion pressure in coronary artery and general peripheral resistance of vessels with maximal effects on 56.8 +/- 2.7, 22.4 +/- 4.7 and 47.2% +/- 6.5% accordingly at most dose 1.5 mgs/kg. Flocalin causes development of cardiodepressive reactions in heart, that is exhibited in dose-dependent the decrease of pressure in the left ventricle, speed of growth (dP/dt(max)) and reduction (dP/dt(min)) in it's of pressure with maximal effects on 37.1 +/- 5.1, 51.2 +/- 9.4 and 55.6% +/- 6.9% accordingly at introduction of most dose of flocalin. Diminish of the cardiac out put and heart rate with a maximal effects on 23.1% +/-12.7% and 19.2% +/- 1.7% accordingly at a dose 1.0 mgs/kg was shown. It should be noted that considerable reduction of heart rate and general peripheral resistance of vessels takes place only at the large doses of flocalin - 1 and 1.5 mgs/kg. Thus, it is shown that activation of K(ATP) channels by flocalin causes the dose-dependent decrease of pressure in the system of circulation of blood and contraction activity of myocardium.
authors.forename: R B
authors.initials: RB
authors.lastname: Strutyns'kyĭ
authors.forename: R A
authors.initials: RA
authors.lastname: Rovenets'
authors.forename: N A
authors.initials: NA
authors.lastname: Strutyns'ka
authors.forename: O P
authors.initials: OP
authors.lastname: Neshcheret
authors.forename: O O
authors.initials: OO
authors.lastname: Moĭbenko
mesh_terms: D000818:Animals; D062186:Arterial Pressure / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects* / Q000502:physiology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D006321:Heart / Q000187:drug effects* / Q000502:physiology; D006339:Heart Rate / Q000187:drug effects; D007275:Injections, Intravenous; D015640:Ion Channel Gating / Q000187:drug effects / Q000502:physiology; D054086:KATP Channels / Q000819:agonists* / Q000378:metabolism; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D020110:Pinacidil / Q000031:analogs & derivatives* / Q000494:pharmacology; D014655:Vascular Resistance / Q000187:drug effects / Q000502:physiology; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology
chemical_list: D054086:KATP Channels; C559719:N-(4-difluoromethoxyphenyl)-N'-pinacolyl-N''-cyanoguanidine; D020110:Pinacidil